Type II JAK2 Inhibitor Gets Off to a Strong Start.
Key claim: AJ1-11095, a type II JAK2 inhibitor, produced impressive clinical responses in a phase I myelofibrosis study and may outperform currently approved type I JAK2 inhibitors.
Abstract
AJ1-11095, a type II JAK2 inhibitor being developed for myelofibrosis, led to impressive clinical responses in a recent phase I study, suggesting that the drug, and perhaps the rest of its still-investigational class, could prove better than currently approved type I JAK2 inhibitors.
Why this matters
AJ1-11095 is the first type II JAK2 inhibitor to reach clinical readout in myelofibrosis, a subtype where type I JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) dominate care but fail to durably suppress the malignant clone and lose activity on progression. An early efficacy signal that appears to exceed approved agents would validate a mechanistically distinct binding mode as a next-generation backbone for PMF, complementing mutant-selective JAK2V617F (PRT12396) and CALR-directed strategies already advancing in the same natural-history niche.